This does not undermine the importance of using gene discovery to develop more effective pharmaceuticals. Rather, it underscores another path for important post-GWAS study that can be useful for reducing the burden of psychiatric and behavioral disorders, namely, as robust genetic variants are identified from GWAS, we have the ability to characterize how measured genetic risk unfolds across development, and in conjunction with the environment, can help guide the development of more effective, targeted prevention programming. This post-GWAS avenue of exploration has not received nearly the attention as the potential for drug development and discovery, but we argue that studying the behavioral and developmental pathways of risk associated with robustly identified genetic variants has the potential to be equally important in terms of future harm reduction. The post-GWAS era1 will allow us to map manifestation of genetic risk across time in order to address questions such as: What phenotypes represent early manifestations of genetic risk that may be intervened upon at an earlier developmental phase to prevent more serious challenges from developing?What do these phenotypes tell us about the underlying
